Related Experiment Video
Updated: May 29, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Systemic therapy of muscle invasive bladder cancer - an update]
1Interne Abteilung mit Herzstation und Dialyse, Krankenhaus der Barmherzigen Brüder, Wien, Austria. dora.niedersuess-beke@bbwien.at
Abstract:
Urothelial cancer is a highly common tumor with increasing incidence worldwide and a peak in the seventh decade. Locally advanced disease has a significant risk for developing metastases. Neoadjuvant, platinum-containing combination chemotherapy improves survival over radical cystectomy. Chemotherapy with gemcitabine plus cisplatin shows equivalent efficacy with less toxicity to MVAC in metastatic setting. New therapy strategies, especially in elderly patients, are urgently needed.
More Related Videos
Related Concept Videos
Treatment Resistent Cancers
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
